EASME

Aromics Biotech is a biotechnology company focused on the discovery and development of innovative drugs and diagnostic methods aimed at addressing significant human diseases and enhancing patients' quality of life. The company specializes in creating anti-tumor and antiviral drugs while providing preclinical development services that involve tracking genomic and proteomic data. This approach enables biotechnologists to identify and validate therapeutic targets, supporting the clinical development process. Aromics Biotech emphasizes the importance of determining clinically predictive molecular endpoints, which assist physicians in managing diseases, guiding prescriptions, and monitoring patient responses to treatment. Through its commitment to utilizing OMIC technologies, Aromics strives to improve drug efficacy and reduce attrition rates in clinical trials.

Ovagen is a biotechnology company specializing in the large-scale production of germ-free chicken eggs and birds, primarily for the pharmaceutical industry. The company's innovative process utilizes a transgenic chicken platform to produce recombinant proteins to Good Manufacturing Practice (GMP) standards. This technology provides pharmaceutical companies with a biosecure and flexible biomanufacturing solution for developing vaccines and therapeutic proteins. In addition to its core offerings, Ovagen also provides Contract Research Services and has expertise in specific poultry and rodent research technologies, as well as in SPF poultry and rodent housing and husbandry.

InProcess-LSP, founded in 2014 by former employees of MSD/Merck, operates from its facilities in Oss, The Netherlands, located within Pivot Park, a hub for innovative pharmaceutical and life-science companies. The company specializes in process analytical technology that offers real-time characterization of nanoparticles during various processes. By integrating advanced spectroscopic optical technologies with sophisticated chemometric modeling, InProcess-LSP provides solutions that enhance operational efficiency and process improvement for its clients in the pharmaceutical and life-sciences sectors.

KronosDNA Srl is a young biomedical company specialized in the reproductive genetics and founded by a team of women, researchers with technical-scientific and managerial expertise. KronosDNA is committed to improving maternal and new born healthcare and facilitating advances in laboratory medicine thanks to the development, prototypization and validation of diagnostic tools to support professionals in the reproductive medicine field.

Vetbiobank is a biotech company specializing in veterinary regenerative medicine. The company develops cell and tissue therapies aimed at enhancing animal health and care. In addition to its focus on veterinary applications, Vetbiobank also engages in human cellular and tissue therapies. It supplies veterinarians with clinical-grade cell and tissue products, thereby supporting medical and scientific needs within the veterinary field. Through its innovative approach, Vetbiobank aims to improve outcomes for animals by advancing regenerative medicine techniques.

PreOmics GmbH, founded in 2016 and based in Planegg, Germany, specializes in mass spectrometry (MS)-based proteomics. The company develops innovative tools, including the iST Kit, designed for efficient sample preparation and peptide pre-fractionation, which allows researchers to process peptide mixtures in just one hour. PreOmics focuses on providing solutions for the identification of protein interaction partners, large-scale protein discovery, and quantification of proteins, as well as the analysis of post-translational modifications. As a spin-off from the Max-Planck Institute of Biochemistry, the company aims to enhance protein analysis for researchers worldwide by offering high-quality technologies that streamline and improve research outcomes.

Inflection Biosciences Ltd. is a drug development company focused on discovering and developing small molecule therapeutics for cancer treatment. Founded in 2012 and based in Dublin, Ireland, with additional operations in London, the company aims to identify promising early-stage cancer research from academic institutions and other organizations globally. Its research pipeline includes innovative PIM kinase inhibitors and multi-targeting kinase inhibitors that are currently in preclinical development. With a team that combines over 60 years of industry experience, Inflection Biosciences is dedicated to advancing its most promising programs through early clinical stages, with plans to partner with larger pharmaceutical companies for later-stage development and commercialization. The company also explores therapeutics for autoimmune and inflammatory diseases, solid tumors, and hematological malignancies, striving to enhance treatment options for healthcare providers.

Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.

7scientists current academic research findings into practical solutions.

Cyclomics is a Dutch startup focused on revolutionizing cancer care through its proprietary circulating tumor DNA (ctDNA) detection technology. This innovative approach aims to provide faster and more reliable diagnoses, particularly for monitoring cancer recurrence and treatment responses, addressing critical clinical needs that current imaging methods struggle to meet. Cyclomics has developed a diagnostic kit, CyclomicsSeq, which offers superior performance compared to traditional radiological and physical examinations. The initial application of this technology targets head and neck cancers, where effective monitoring of treatment response and recurrence is vital for improving patient survival rates. By enabling accurate measurements and timely interventions, Cyclomics seeks to significantly enhance cancer diagnostics and patient outcomes.

Enzymlogic specializes in enzymology and protein science, offering analytical services aimed at enhancing drug discovery and development for the pharmaceutical and biotech industries. The company assists in identifying kinetic profiles during the drug development process, which helps clinicians understand the interactions between drugs and their targets. This insight is crucial for evaluating factors that influence efficacy and safety, ultimately contributing to the creation of innovative therapies that improve patients' quality of life. Enzymlogic aims to become a key resource for organizations focused on successful drug discovery, ensuring their clients achieve optimal returns on investment while advancing therapeutic solutions.

Samplix is a biotechnology company based in Herlev, Denmark, focused on single-molecule sample preparation for DNA and RNA. It has developed the Xdrop™ technology, which utilizes a unique “water-oil-water” droplet system to create millions of reaction chambers for handling individual DNA molecules. This innovative approach allows for targeted enrichment of large DNA fragments and enables researchers to sequence specific genetic regions effectively. Samplix's technology addresses the limitations of existing multi-molecule preparation methods, providing enhanced precision and sensitivity while simplifying the sample preparation process. Its solutions empower scientists to make informed research decisions, particularly in applications related to virus integration and CRISPR editing.

TransCure bioServices SAS, founded in 2012 and located in Archamps, France, specializes in vivo pharmacology preclinical services tailored for pharmaceutical, biotech, start-up, and academic researchers. The company offers unique research and development platforms, including the Humanized Immune System (HIS) and Human Immunodeficiency Virus (HIV) mouse models. These platforms are accessible as fee-for-service solutions, enabling clients to profile new drugs targeting immuno-related diseases and develop novel anti-HIV/AIDS therapies. By providing humanized mouse models that better predict human drug responses compared to traditional models, TransCure bioServices helps accelerate the development and commercialization of new drugs and therapies, facilitating a more efficient pathway for researchers to bring innovative treatments to market.

BioCom is a highly innovative Company in the biomedical sector, focused on research, development and manufacture of cutting-edge medical devices, as well as the development of new technologies for surgery, diagnostics and biomedical research.

Beta Bugs is an insect genetics company focused on developing high-performance breeds of Black Soldier Fly for insect farmers. The company's primary mission is to enhance the productivity of the insect protein sector, making it competitive with traditional feed ingredients such as fishmeal and soymeal. To achieve this, Beta Bugs operates a breeding program called HiPer-Fly® and runs an egg production site known as The Multiplier®, supplying its breeds to both UK and international markets. By leveraging biotechnology and breeding techniques, Beta Bugs aims to establish a sustainable protein source that converts food waste into high-quality protein for use in livestock, aquaculture, and pet feed, thereby providing an alternative to conventional feed sources. The company is headquartered at the Easter Bush Campus, collaborating with the Roslin Institute, a leader in animal genetics.

Diapath S.p.A. is a privately held company that specializes in the anatomic pathology sector, providing a range of high-quality products and customized services to hospitals and laboratories globally. The company manufactures reagents, medical instruments, and consumables designed for modern anatomical and cytology laboratories. Its product lineup includes high-tech instruments, stains, tissue processing dyes, and microtomy supplies, all developed to meet rigorous quality standards. With a commitment to innovation and reliability, Diapath aims to establish itself as a leading brand in anatomic pathology, emphasizing customer needs and delivering tailored solutions.

Astraveus is transforming cell and gene therapy (CGT) manufacturing through its Lakhesys™ platform, an innovative cell foundry that leverages deep process optimization and microfluidic bioprocessors. This technology allows for the production of personalized biological therapies with minimal infrastructure requirements, ultimately reducing costs and addressing logistical challenges in the industry. By automating autologous bioproduction, the platform enhances the efficiency of transforming cells into therapeutic agents, enabling healthcare providers to scale the development and manufacturing of CGT solutions. Astraveus aims to improve patient access to these vital therapies while minimizing environmental impact.

Microbium is an R&D company specializing in custom microbiological detection protocols tailored for specific industrial samples. Founded to address the industry's challenges with microbial contamination, Microbium integrates closely with national laboratories and analytical organizations across Russia, Denmark, and Slovenia. The company offers solutions that go beyond conventional microbiological methods, providing rapid analysis suitable for various sectors. Additionally, Microbium has developed electronic devices capable of detecting and eliminating microorganisms in drinking water, wastewater, and products from the chemical and food industries. These devices automate the detection and counting of harmful bacteria, such as E. coli and coliforms, while employing bioremediation processes to effectively remove contaminants. This innovation not only helps users identify and mitigate contaminated areas but also contributes to reducing production costs and lowering the carbon footprint associated with industrial processes.

Poly-Pico Ltd, based in Cork, Ireland, specializes in innovative fluid dispensing technology developed from five years of research at the University of Limerick. The company designs and manufactures solutions for both Life Science and Industrial applications, serving prominent institutions such as NASA and Harvard. As a leading microdispensing specialist, Poly-Pico focuses on research and development to create advancements in liquid handling, including contactless biology techniques like levitating microdrops and non-contact ultra-low volume acoustic dispensing. This core technology addresses challenges such as cross-contamination and dispenser clogging while minimizing wastage through the use of simple, disposable cartridges. Poly-Pico's multidisciplinary team possesses expertise in micro-fluidics, electronics, mechanical engineering, and biotechnology, allowing them to offer both standard and customized solutions tailored to meet precise dispensing needs.

Cellestia Biotech AG is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies for cancer and immunological disorders. Founded in 2014 as a spin-off from the École Polytechnique Fédérale de Lausanne, the company is headquartered in Basel, Switzerland, with an additional location in Lausanne. Cellestia focuses on its lead compound, CB-103, which is a novel oral pan-NOTCH inhibitor targeting NOTCH-dependent leukemia, lymphoma, and solid tumors. The drug has successfully advanced to Phase 2 clinical trials for patients with multi-drug resistant cancers. In addition to CB-103, Cellestia is developing a pipeline of novel transcription factor inhibitors and NOTCH-specific biomarkers to enhance patient selection and treatment outcomes. The company's approach aims to control and modulate pathogenic gene expression through selective inhibition of transcription factors in the cell nucleus, contributing to integrated drug and personalized medicine development.

Immundnz is an immunology CRO specialised in immune modelling, immune response and tissue damage analysis, in vivo and in vitro cell culture systems for preclinical drug research and development. We are different because we are experienced scientists who will design an experimental model and use customised assays as well as standard assays tailored for the right solution for your problem. We will develop novel assays in our laboratory to meet your specific and unconventional need.

Seaweed Solutions AS is a seaweed cultivator and innovator established in 2009, focusing on large-scale ocean farming of seaweed for various applications, including food, feed, pharmaceuticals, and biomaterials. The company has established itself as a leader in European seaweed cultivation, controlling the entire value chain from proprietary seed hatcheries to processing plants. With a patented cultivation technology called Seaweed Carrier, Seaweed Solutions combines extensive knowledge in marine biology and engineering to pioneer modern seaweed farming practices. Its primary operations are based in Norway, where it manages the largest seaweed farms in Europe dedicated to brown macroalgae. The company's objectives include becoming the leading supplier of cultivated biological seaweed and seaweed seeds in Europe. Additionally, Seaweed Solutions forms partnerships and offers turnkey solutions related to cultivation technology, raw material sourcing, market development, and environmental services, thereby supporting sustainable practices in the seaweed industry.

OmniSpirant develops regenerative gene therapies with the potential to transform respiratory medicine.

BioMensio Ltd. is a biotechnology company based in Tampere, Finland, established in 2015. It specializes in developing smart multi-analyte handheld detection devices for bio-analytics, providing rapid and on-site detection of various biological targets from a small sample in a single step. The company's offerings include a novel miniaturized micro-array platform that supports the quick development of new bio-screening applications, which are applicable in areas such as saliva testing, food and milk safety, point-of-care diagnostics, and bio-security. BioMensio's technology enables the creation of label-free assays, allowing for the detection of multiple analytes without the need for labeling procedures. Additionally, its Diagnostics-as-a-Service (DXaaS) platform integrates a handheld reader, multianalyte fluid cartridges, and cloud-based analytics, facilitating easier access for original equipment manufacturers (OEM) to develop bio-analysis products and services.

TYDOCK PHARMA Srl is a knowledge-based biotechnology SME set up in 2006. In 2009, it received an award for being one of the most promising and innovative biotechnology companies in Italy from The Italian Institute for Foreign Trade (I.C.E.). The company is based on integrated drug discovery know-how which relies on 20 years of experience. It is a leading player in the drug discovery field and has seen many collaborations with universities and other biotechnology companies. The Company, as Research and Technology Transfer Centre, is also the recipient of research grants from the European Commission (FP7). TYDOCK PHARMA mainly operates in two business areas: DRUG DISCOVERY PRODUCTS TYDOCK PHARMA focuses on the discovery and early development of chemotherapeutic drugs, with particular emphasis on parasitic diseases (tuberculosis, malaria and protozoarian infections). INNOVATION PROJECT DEVELOPMENT TYDOCK PHARMA is involved in various technology transfer projects aimed at translating innovative technologies from basic research to industrial application.

MycoSolutions AG specializes in developing customized soil additives designed to protect and maintain trees, particularly veteran specimens. Based in St. Gallen, Switzerland, the company offers a range of services including the diagnosis of fungal pathogens, visual tree inspections, hazard assessments, and the development of tailor-made plant growth promoters. MycoSolutions is recognized as a technology leader in the efficient use of mushrooms, leveraging the expertise of its founders and employees to provide environmentally friendly alternatives to conventional wood preservatives and agricultural pesticides. The company's commitment to sustainability aims to reduce the environmental impact of harmful chemicals, while its educational initiatives include training sessions and publications to enhance knowledge in tree care and soil health.

Bioithas is a biotechnology company dedicated to medical research. Its primary focus is the development of natural treatments that target the root cause of health issues, rather than just symptoms. The company conducts clinical trials in humans to test and validate its personalized treatments, aiming to enhance users' quality of life and overall well-being.

Chemicare is a biotechnology company established in December 2016, focused on the discovery and development of orphan drugs for patients with calcium-related genetic diseases. The company aims to improve the quality of life for individuals suffering from conditions such as Tubular Aggregate Myopathy, York Platelet Syndrome, and Stormorken Syndrome. Chemicare is dedicated to creating therapies that address the abnormal intracellular calcium levels characteristic of these rare diseases, enabling healthcare professionals to provide effective treatment options for affected patients.

FGen GmbH, founded in 2011 in Basel, Switzerland, specializes in the development of a nanoliter-reactor platform for high-throughput phenotypic analysis of cellular libraries. This innovative approach facilitates the discovery and optimization of biological activities. As a contract research organization, FGen collaborates with partners in the biotechnology, life sciences, and pharmaceutical sectors to establish efficient bioprocesses and develop new biopharmaceuticals. The company also focuses on creating optimized microbial strains for various biotechnological applications, utilizing proprietary screening technology alongside biological engineering tools. This enables clients to achieve efficient and cost-competitive production of chemicals and proteins.

Next Generation Sensors is a biotech business that creates mass spectrometers for commercial uses in the life sciences. Finding rapid, accurate screening information for potential health, security, and environmental hazards relies on. By bringing the lab to the sample with portable, sensitive, accurate, and user-friendly technology for quick detection of dangerous compounds in our food, bodies, and environment, offers answers for a safer future.

RemAb Therapeutics specializes in the development of polymeric glycoconjugate molecules aimed at addressing nosocomial infections. The company's innovative technology focuses on eliminating non-neutralizing natural antibodies that hinder the immune system's natural response and promote pathogen proliferation. By targeting these antibodies, RemAb Therapeutics seeks to provide medical practitioners with effective new strategies for both treating and preventing a range of pathological infections, enhancing patient outcomes in the process.

Clover Bioanalytical is a bioinformatics company that specializes in data processing for bioanalytical chemistry and clinical diagnostics applications, particularly utilizing mass spectrometry. Founded by a team of Ph.D. graduates with expertise in both business and research, the company focuses on developing advanced software and statistical analysis tools for the biomedical field. Clover’s capabilities extend beyond mass spectrometry to include medical image processing and both univariate and multivariate statistical analysis, addressing the challenges posed by Big Data. The company emphasizes a customer-oriented approach, aligning its solutions with the specific goals and scalability needs of its clients. By leveraging artificial intelligence, Clover aims to enhance the rapid identification of microorganisms, positioning itself as a key partner for hospitals, research institutions, and biotechnology companies in tackling significant scientific questions.

Sepsia Therapeutics is developing new broad-spectrum drug and cellular therapies against sepsis, a life-threatening condition caused by the host response to an infectious agent, mostly bacterial and fungal. Their strategies are based on the host’s scavenger-like receptors present on lymphocyte cell surfaces, which bind to and neutralize the conserved inflammation-promoting structures of bacteria and fungi that cause sepsis. These structures provide novel therapeutic targets aimed at both, microbial virulence factors and host inflammatory and immune mediators,

ImmuneBiotech AB, founded in 2013 and based in Lund, Sweden, specializes in the research and development of innovative microbiome therapeutics. The company focuses on creating novel probiotics derived from lactic acid bacteria and synbiotic formulations that aim to influence gut microbiota and immune system responses. ImmuneBiotech's therapeutic products include combinations of probiotics, prebiotics, and proteins, specifically designed to address various inflammatory disorders such as multiple sclerosis, rheumatoid arthritis, and type 1 diabetes. By leveraging its online platform, the company seeks to enable healthcare professionals to prevent and treat autoimmune and other chronic inflammatory conditions effectively.

InSCREENeX GmbH is a biotechnology company based in Braunschweig, Germany, founded by Dr. Roland Schucht as a spin-off from the Helmholtz Centre for Infection Research. The company specializes in cellular screening technologies aimed at accelerating the drug discovery process for pharmaceutical and drug development firms. By employing advanced genetic manipulation techniques, InSCREENeX develops innovative and user-friendly mammalian cell systems that serve as effective decision-making tools throughout the drug development pipeline. The company's offerings include the generation of specialized cell lines for primary screening and the design of physiologically relevant cell types for secondary screening and profiling, ultimately reducing the time and costs associated with biopharmaceutical drug discovery and validation.

Delta Diagnostics, founded in 2018 as a spin-off from TNO – The Netherlands Organisation for Applied Scientific Research, specializes in photonic biosensor technology. The company leverages patented innovations developed in TNO's Optics department to commercialize rapid, sensitive, and low-cost biosensors and instruments. These advanced biosensors utilize integrated photonics and optical chips containing waveguides that facilitate the transportation of light across multiple sensors. This technology enables real-time, label-free monitoring of biomarkers, allowing for accurate concentration measurements within minutes. Delta Diagnostics aims to enhance research in life sciences and facilitate the development of novel diagnostics through its innovative biosensing solutions.

300K is a biotechnology start-up composed of a multidisciplinary team with expertise in developing and commercializing innovative life sciences products and services. The company specializes in creating solutions for the storage and shipment of bio-specimens at room temperature. Its stabilization technology enhances the preservation of biological samples, ensuring a secure process while optimizing storage space in life science facilities. By enabling laboratories to stabilize biospecimens at room temperature, 300K aims to minimize sample loss and improve the overall efficiency of biosample management.

MDxHealth is a molecular diagnostics company focused on developing and commercializing advanced epigenetic tests to assist in the detection and treatment of cancer. The company's product portfolio includes ConfirmMDx, a prostate cancer test aimed at addressing false-negative biopsy concerns; SelectMDx, which guides repeat biopsies for prostate cancer; AssureMDx, a noninvasive liquid biopsy test for bladder cancer; and PredictMDx for Glioblastoma, a tissue methylation test that aids in treatment decisions for brain cancer. Established in 2003 and headquartered in Irvine, California, with additional offices in Belgium and the Netherlands, MDxHealth leverages proprietary genomic and epigenetic technologies to provide actionable diagnostic information. The company's revenue is generated through clinical laboratory services and out-licensing of its patented DNA methylation platform and biomarkers, serving markets primarily in the United States and Europe.

Mercurna B.V. is a biotechnology company based in Oss, Netherlands, founded in 2017. The company focuses on the synthesis of messenger RNA (mRNA) and the development of therapies aimed at treating chronic kidney diseases. As a startup in the biotech sector, Mercurna is dedicated to delivering innovative precision medicine solutions specifically designed for patients suffering from chronic kidney conditions.

Biome Makers Inc. is a biotechnology company based in San Francisco, California, founded in 2015. The company specializes in understanding and identifying microbiomes, particularly in the context of agriculture. By utilizing DNA sequencing technologies and proprietary Intelligent Computing systems, Biome Makers provides detailed, crop-specific insights and recommendations to enhance agricultural production and product quality. Their technology enables growers and manufacturers to analyze soil ecosystems effectively, offering data-driven insights that facilitate improved decision-making in farming practices.

DELMIC specializes in correlative light and electron microscopy technology, focusing on applications in life and materials science research. The company offers a range of services, including cathodoluminescence, automated cryo-electron tomography workflows, and efficient electron microscopy solutions. These services are designed to enhance research capabilities by providing reliable and high-throughput methodologies, enabling researchers and organizations to gain insights more quickly and effectively. Through its innovative tools and integrated microscopy approaches, DELMIC aims to facilitate advancements in scientific research.

Bioengineering Laboratories SRL, based in Cantu, Italy, specializes in the design, development, manufacturing, and distribution of medical devices within the bioengineering sector. The company provides a diverse range of products, including those for urodynamics, dialysis, gynecology, extracorporeal circulation, and cardiac surgery. With over twenty years of experience, Bioengineering Laboratories focuses on innovative solutions and is committed to modern design principles in the medical field. The organization emphasizes a comprehensive understanding of market needs, an openness to new clinical techniques, and adherence to regulatory standards. Additionally, it offers advisory services related to the design, industrialization, and production of medical devices, ensuring a thorough approach to the engineering of life-enhancing technologies.

Biocompatibility Innovation (BCI), established in 2014 in Padua, Italy, specializes in biotechnologies for biomedical applications. The company develops and manufactures highly biocompatible implantable prostheses, both biological and polymeric, using its proprietary FACTA® and PROTEGO technologies. These innovations extend the lifespan of bioprostheses and enhance the biocompatibility of implantable medical devices. BCI also provides third-party testing services and develops new proprietary treatments. Led by experienced researchers and managers in biotech and biomedicine, BCI aims to improve clinical management, patient quality of life, and lower healthcare costs.

NG Biotechnology is a biotechnology company established with long-term investments with the partnership structure of academicians who produce microbial cultures with years of experience in environmental biotechnologies and have worked on environmental and agricultural microbiology in established institutions abroad for many years.

omicX operates a platform that facilitates access to bioinformatics tools for scientists and developers. Founded in 2012 and based in Le Petit Quevilly, France, the company offers OMICtools, a resource designed to help users navigate the vast array of biotechnology tools available. By leveraging collective intelligence in bioinformatics, omicX aims to exploit biological Big Data across various applications, including biotechnology, life sciences, medicine, agriculture, and industry. The platform not only provides information on tools for managing and analyzing extensive biological data but also fosters interaction within the scientific community by allowing users to pose questions, share expertise, and provide feedback on tools. This approach has established omicX as a trusted leader and reference point in bioinformatics, attracting users from prominent universities, medical institutions, pharmaceutical companies, and the biotech industry.

RegStem is an early-stage biopharmaceutical company dedicated to repurposing existing molecules and developing new treatments in regenerative medicine, particularly targeting rare muscle and blood diseases with significant unmet medical needs. The company focuses on research, development, and licensing of innovative molecules for human therapies. Its efforts include repurposing drugs for the reconstitution and repair of bone marrow during acute aplasia and promoting skin regeneration after scarring by stimulating and controlling the differentiation of stem cells. Through these initiatives, RegStem aims to provide effective solutions for patients suffering from chronic skin diseases and other serious conditions.

Iris.ai offers an AI-powered science assistant designed to enhance the efficiency of research and development departments by facilitating the navigation of scientific literature. Its primary product, RSpace, features advanced search capabilities, smart filters, reading list analysis, auto-generated summaries, and automated data extraction, enabling users to systematically organize information. By leveraging natural language processing algorithms, Iris.ai addresses the challenges of factuality tracking in AI, providing tools that enhance the accuracy and reliability of scientific research. This platform is aimed at both corporate R&D teams and academic researchers, allowing them to uncover new scientific insights that go beyond traditional human capabilities.

Depixus is a biotechnology company that has developed a novel technology designed for real-time analysis of individual biomolecular interactions at a large scale. Its platform enables comprehensive genome analysis, allowing researchers to examine entire genomic regions quickly and efficiently. This integrated system provides the flexibility to specify the desired level of sequence and epigenetic detail, facilitating the discovery of new biological pathways and the decoding of disease mechanisms. By enhancing the understanding of these processes, Depixus aims to contribute to the development of new precision medicines. The company's focus on advanced DNA and RNA sequencing technologies addresses the limitations of current methods, particularly in achieving single-molecule precision.

Biodentify was founded as a spin out from Dutch R&D group TNO, in December 2014. TNO is a 3000+ R&D organization, hosting the largest Microbiological research group in the Netherlands. It is owned and managed by JOA Ventures, 3 partners with extensive entrepreneurial experience bringing innovative technologies to market in the Oil & Gas industry. The company has developed a novel technology, predicting prospectivity before drilling, with approx. 70% accuracy, based on microbiological DNA analysis of shallow soil or seabed samples.

Biprocel is a biotechnological company.

Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

AcouSort is a Swedish company specializing in the development and sale of laboratory products and integrated solutions that utilize ultrasound technology for the separation, washing, and enrichment of biological samples. Its offerings cater to researchers and life science companies, focusing on the automated preparation of samples such as blood cells, bacteria, and extracellular vesicles. The technology is rooted in acoustofluidics research from the esteemed group led by Professor Thomas Laurell at Lund University's Department of Biomedical Engineering. Key products include AcouTrap, AcouWash, and AcouPlasma, which facilitate efficient handling of microscopic particles in microfluidic channels for research and diagnostic applications.

Oxoprobics microplates provide a powerful tool and biological services based on this technology for obtaining proof of mechanism data, useful as first exploratory assessments, refocusing and adapting new tailored methodologies for its use in cell biology (e.g. mitochondrial inhibition or uncoupling, stimulation or inhibition of oxygen-consuming reactions catalyzed by enzymes, antibiotic resistance, etc.) or Immunology (lymphoproliferation kinetics in whole blood, antigen recognition and sensitivity, etc.).

Cellink AB is a biotechnology company specializing in bioprinting technologies that enable the 3D printing of human organs and tissue models, aimed at applications in pharmaceutical, cosmetic, and medical research. Founded in 2016 and headquartered in Gothenburg, Sweden, with an office in Palo Alto, California, Cellink offers a range of products including bioprinters, imaging systems, dispensing solutions, and bioinks that cater to the needs of researchers and laboratories worldwide. Its product lineup features various bioprinting platforms such as BIO X and BIO X6, along with specialized solutions for skin and cartilage tissue, microfluidics, and single-cell dispensing technologies. Cellink’s bioinks are utilized for diverse applications including drug screening, tissue regeneration, and organoids. The company serves a global customer base that includes universities, hospitals, and public laboratories, and it has established collaborations with organizations like MedImmune and Made In Space, Inc., to further its mission of advancing bioprinting technology in medicine.

KerLine is an innovative start-up and a spin-off company of the Institute of Organic Synthesis and Photoreactivity (ISOF) of the Italian National Research Council (CNR) in Bologna. KerLine founders have developed an outstanding experience in full-length keratin manufacturing and engineering. In particular, they set up a method for the chemical extraction of high molecular weight keratin from natural waste of agrifood and textile industries. The unique properties of the extracted keratin allow its application in different technological fields. The company is located within the Bologna CNR research area.

ProtoQSAR is a company focused on the application of computational methods to the prediction of physico-chemical and/or biological properties of chemicals.

Biomax Informatics AG, founded in 1997 and based in Planegg, Germany, specializes in developing customized bioinformatics solutions for life science organizations, including those in drug discovery, diagnostics, and agriculture. The company offers a range of products, such as the BioXM Knowledge Management Environment, which enables the creation, management, and visualization of scientific models. This platform enhances communication and collaboration across research departments while integrating with existing IT systems. Other notable offerings include the BioRS Integration and Retrieval System for biological data, the Pedant-Pro Sequence Analysis Suite for microbial genome analysis, the Viscovery data mining suite, and NeuroXM for brain science applications. Biomax emphasizes systematic knowledge management to help clients navigate the complexities of unstructured data, supporting efficient decision-making and the acceleration of biotechnological research and development. The company has a team of approximately 50 multidisciplinary scientists and engineers, fostering long-term relationships with clients and ensuring the delivery of state-of-the-art solutions.

Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016 and based in Barcelona, Spain, the company specializes in creating non-invasive tests for the in-situ diagnosis of various cancers using patients' blood. It also develops in-vivo diagnosis systems that assist in surgical procedures and monitor patient conditions, alongside therapeutical drugs aimed at treating cancer. Moirai Biodesign's innovative pipeline includes RNA biomarker discovery, the design of plug-and-play bio devices, and advanced platform delivery systems, all aimed at improving early cancer detection and targeted treatment options.

CytaCoat is a private Swedish company headquartered in the Karolinska Institutet Science Park in Solna, established by researchers from the Karolinska Institute and the Royal Institute of Technology. The company focuses on developing an innovative antibacterial coating technology for medical devices aimed at preventing healthcare-associated infections. Their proprietary polymer surface demonstrates effectiveness against several problematic pathogenic bacteria, addressing a significant challenge in healthcare. CytaCoat’s technology is designed to be stable under varying pH and ionic conditions, minimizing the release of potentially toxic components and preventing bacterial colonization without relying on antibiotics, which can lead to resistance. The company operates a fully equipped laboratory for microbiology evaluations and technology optimization, and it has established collaborations with clinical partners at the Karolinska University Hospital. Additionally, CytaCoat works with consultants specializing in regulatory affairs, clinical research, patenting, and specialized analyses to advance their product towards commercial viability and licensing opportunities.

Ophiomics S.A. is a clinical-stage biotech company based in Lisbon, Portugal, specializing in the development of diagnostic products and services for liver cancer. Established in 2015, Ophiomics focuses on integrating bioinformatics, artificial intelligence, and genomics to enhance diagnostic and prognostic capabilities in oncology. The company is ISO 13485 and ISO 9001 certified, ensuring adherence to high-quality standards in its operations. Its product pipeline encompasses various stages of development, including pre-clinical programs and those undergoing clinical validation. Ophiomics aims to improve early detection of liver cancer through biomarker-based diagnostic devices that combine molecular signatures with clinical parameters in predictive algorithms, ultimately assisting healthcare providers in treatment selection and clinical follow-up for better patient outcomes.

BioBlocks is a collaborative medicinal chemistry research organization dedicated to advancing drug discovery from initial lead identification to the selection of development candidates. The company focuses on empowering scientists through collaboration, working closely with clients to uncover compounds that are suitable for progression to phase two clinical trials. BioBlocks offers a comprehensive drug discovery platform that includes a fragment library and compound database, facilitating the identification of viable chemical entities for various biological pathways. In addition to its core drug discovery services, the organization provides preclinical development and clinical trial management, enabling pharmaceutical companies to enhance project execution with improved effectiveness, speed, and reliability.

ReproPharm Vet is a biotechnology company focused on improving livestock breeding through sustainable agricultural practices. It develops user-friendly tools aimed at enhancing the management of livestock breeding while addressing key factors such as economic competitiveness, workload reduction, environmental protection, and animal welfare. ReproPharm's products serve a diverse range of professionals in the industry, including farmers, scientists, artificial insemination technicians, and veterinarians, and are designed for use both on farms and in laboratories. The company's commitment to innovation ensures that it meets the evolving demands of consumers and the livestock breeding market, facilitating efficient and responsible breeding practices.

Prasinotech is a trading and biotechnology company delivering healthy and natural ingredients for use in cosmetic, food and pharmaceutical products Prasinotech focuses primarily on producing polysaccharide products from natural marine sources. Being the first company in the world to specialise in polysaccharide products derived from microalgae, Prasinotech takes a leading position in what we believe will be the future in sustainable production of natural ingredients.

Inpharmatis offers comprehensive regulatory affairs services to Life Science Industry including Drug Development and Vigilance Services to pharmaceutical, medical device, food supplements, cosmetic and biotech companies. Their area of expertise lies in the European & CIS market. A multi-disciplinary team of qualified regulatory affairs consultants is at your disposal for all aspects of your marketing authorisation applications for active substances and human medicinal products. Inpharmatis shall provide full regulatory support over the whole life cycle of your product.

Senolytic Therapeutics is a operator of a pharmaceutical company intended to develop medicines and therapeutics for patients affected by age-related diseases. The company's medicines target and eliminate damaged cells, enabling healthcare providers to improve the lives of those affected by diseases associated with aging.

TSE Systems GmbH is a manufacturer of advanced analysis and measurement systems tailored for preclinical research within the pharmaceutical industry. The company offers a diverse range of products, including conditioning and response systems, home cage systems, sensors, and tracking devices designed for behavioral applications. Additionally, TSE Systems provides inhalation systems, metabolic monitoring tools, and software solutions for analyzing behavior, tissues, and physiological metrics. With a focus on modular designs, the company aims to deliver integrated hardware and software platforms that support neuroscience, phenotyping, drug screening, and toxicology research. Established in 1886 and headquartered in Bad Homburg, Germany, TSE Systems also maintains an office in Chesterfield, Missouri, enhancing its global service capabilities.

AXO Science is dedicated to enhancing public health through the development of innovative diagnostic solutions. The company has created a forensic testing tool that offers multi-parameter diagnostic characterizations. This sophisticated tool features an integrated biochip, which incorporates multiple oligonucleotide probes grafted onto a polymer membrane. As a result, forensic departments and diagnostic enterprises can utilize advanced technologies for molecular-based diagnosis, improving their capabilities in the field of diagnostics.

React4life is an Italian biotech company established in 2016 by Silvia Scaglione and Maurizio Aiello, following over 15 years of research and development. The company focuses on advancing biomedical research through its innovative technology, MIVO® (Multi In Vitro Organ), which represents a next-generation organ-on-a-chip system. This microphysiological platform allows researchers to simulate human biology more accurately in laboratory settings, addressing the limitations of traditional in vitro assays and animal testing. React4life's technology enhances the reliability and predictivity of various applications, including pharmaceutical drug testing, personalized medicine, immuno-oncology therapies, cosmetics, dermatology, and nutraceuticals. By enabling the cultivation of three-dimensional human-like tissues for in vitro testing, React4life aims to improve the effectiveness of laboratory experiments and promote ethical research practices.

LifeTag is a Portuguese technology startup that specializes in the research and development of non-invasive diagnostic technologies aimed at evaluating metabolism and diagnosing various high-incidence metabolic diseases, such as diabetes, obesity, and metabolic syndrome. The company has developed a diagnostic marker that facilitates non-invasive health monitoring, particularly focusing on intestinal permeability to enhance the accuracy of chronic metabolic disease diagnoses. By providing healthcare professionals with effective tools to assess patients without causing discomfort or side effects, LifeTag aims to improve health outcomes and streamline the diagnostic process.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses aimed at enhancing cancer treatments. The company's patented technology focuses on using these viruses to improve tumor T-cell therapies, including tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibitors. TILT Biotherapeutics is recognized as a leader in the global market for integrating oncolytic viruses with cancer immunotherapy. Their product pipeline includes TILT-123, TILT-234, and TILT-321, which are designed to modify the tumor microenvironment and counteract its suppression of immune responses. The innovative approach has the potential to replicate the successes seen in CAR-T therapy for solid tumors, similar to those achieved in hematological cancers.

BioApplications provides smart probiotic solutions.

Biomode is a Portuguese startup located in Caldas das Taipas that specializes in developing rapid and accurate molecular diagnostic tests for identifying pathogens within the food, environmental, and life sciences sectors. Utilizing Peptide Nucleic Acid Fluorescence In Situ Hybridization (PNA-FISH) technology, Biomode's diagnostic kits provide a streamlined approach that eliminates the need for DNA extraction or amplification, ensuring reliability in the presence of inhibitory compounds and focusing solely on viable bacterial cells. The company plans to launch its first product, Probe4Salmonella®, for detecting Salmonella in food samples, followed by additional kits for Listeria monocytogenes and E. coli O157:H7. In the clinical diagnostics realm, Biomode has developed Probe4Pylori®, which is designed for the rapid identification of clarithromycin-resistant Helicobacter pylori strains and is currently seeking investigational device exemption from the FDA to commence field trials. Founded by researchers from the universities of Minho and Porto, Biomode aims to enhance pathogen detection in both food safety and health diagnostics.

Bioaxial specializes in advanced microscopy technology, focusing on super-resolved fluorescence microscopy for extended live cell imaging. Their proprietary optical modules, designed to enhance commercial microscopes, enable imaging with a resolution of less than 100 nanometers. The company holds five exclusive patents, reflecting its innovative approach to improving live cell imaging.

Nanosynex is a diagnostic test that checks bacterial resistance to antibiotics in a record time, using a phenotypic approach that involves microfluidic techniques and fluorescent-based analysis. The test helps doctors determine faster (same-day results) the most appropriate antibiotic treatment for their patients, helping them recover in a shorter time and preventing the spread of resistant bacteria in the environment. By limiting prolonged hospitalization, Nanosynex allows to save significant healthcare costs.

BunyaVax is a biopharmaceutical company focused on developing vaccines for infectious diseases and cancer using its proprietary vaccine platform technology. The company employs a unique "Plug and Play" approach that allows for the rapid generation of potent vaccines capable of encoding a wide range of antigens. This innovative technology has applications in both veterinary and human medicine, positioning BunyaVax to address diverse health challenges through effective vaccination strategies. By shifting its focus in vaccine development, BunyaVax aims to enhance the safety and efficacy of vaccines, contributing to improved health outcomes.

SunRegen is a biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, including neurological, neuromuscular, and ophthalmic disorders. The company is focused on creating drug candidates that demonstrate neuroprotective effects and promote neurite outgrowth, particularly targeting conditions such as primary optical atrophy, ALS, Huntington's disease, Alzheimer's, and Parkinson's disease. SunRegen's team comprises experienced professionals with backgrounds in drug development and clinical research, aiming to deliver effective therapies that can significantly improve the lives of patients suffering from these challenging conditions. Their commitment to bringing life-changing treatments to the market informs all aspects of their work.

BioCopy is a company focused on developing a patented technology that allows for the efficient copying of biomolecules, similar to how a photocopier functions. This innovative approach simplifies the complex process of navigating the immune system, which is essential for advancing therapies for tumors and autoimmune diseases. The technology has broad applications, including diagnostics, vaccine development, and the screening of potential drug candidates. By enabling the replication of biomolecules, BioCopy provides valuable tools for researchers and healthcare professionals in the fields of medicine and biotechnology.

Pharmaceutical Biotechnology focuses on the development and implementation of new biotech projects with high market potential. They develop, research, and manufacture biotech products with a focus on food, pharmaceutical, hygienic, cosmetic, and environmental applications.

Avectas is a cell engineering technology company, enabling drug developers to manufacture potent engineered cell therapies at therapeutic volumes, with high efficiency and with minimal cell disruption. Avectas technology delivers advanced molecules such as mRNA, proteins and gene editing tools to a range of cell types including T cells for immuno-oncology applications. Unlike the current industry standard of vector-free delivery methods, cells engineered with Avectas technology require no recovery time, leading to a shorter, simpler, more cost effective process.

SynAct Pharma AB, based in Lund, Sweden, focuses on developing treatments for acute exacerbations in inflammatory diseases through its subsidiary, SynAct Pharma ApS. The company’s lead drug candidate, AP1189, targets arthritis, including psoriatic arthritis, which affects a significant proportion of psoriasis patients. Preclinical studies indicate that AP1189 possesses a distinctive ability to reduce inflammation while promoting bleeding, potentially mitigating joint damage following acute inflammatory episodes. The drug is designed for convenient once-daily oral administration. SynAct Pharma aims to advance AP1189 through clinical trials, with results from a Phase I study anticipated. Following safety and tolerability evaluations, the company plans to pursue a clinical trial application for patients with active arthritis, and upon successful proof of concept, intends to establish commercial partnerships with major pharmaceutical firms.

Leukos Biotech is a biopharmaceutical company established in 2015 as a spin-off from the Josep Carreras Leukaemia Research Institute. The company focuses on developing innovative treatments for Acute Myeloid Leukaemia (AML) and other blood cancers. It specializes in identifying new therapeutic targets against leukemic stem cells in AML, utilizing repurposed small molecules to improve diagnosis and prognosis for patients. Leukos Biotech benefits from strong scientific and financial support from the Josep Carreras Leukaemia Research Institute and the Josep Carreras Leukaemia Foundation, among other collaborators, enhancing its capacity to address critical health challenges associated with haematological malignancies.

WellGenetics was founded in July 2014. WellGenetics is dedicated to providing researchers professional services in generating transgenes and gene knockout/knockin in fly and mosquito models. They are an independent company from any academic research institutes. With strong and solid background in Drosophila genetics, their team are composed of experts in molecular biology and in microinjection for generating variety of genetic tools, such as gene deletion, point mutation, gene reporters, tag knockin and RMCE knockin with/without selection marker to level-up your research quality. Each project will be designed, executed, and supervised by postdoctoral scientists, thus to ensure the quality and reliability of entire experiment process.

Cergentis is a biotechnology company that specializes in genomics study services, focusing on enhancing the quality of genetic research and human healthcare. Established in 2012 as a spin-off from the Royal Netherlands Academy of Arts and Sciences and its Hubrecht Institute for Developmental Biology & Stem Cell Research, Cergentis leverages its proprietary Targeted Locus Amplification (TLA) technology to offer services and kits that facilitate cost-effective and comprehensive sequencing of important genes and genomic regions. The company collaborates with leading research institutes, diagnostic laboratories, and pharmaceutical and biotech firms worldwide, contributing to advancements in genetic cancer research and diagnostics. By enabling the sequencing of genes of interest, Cergentis plays a vital role in accelerating the development of new treatments aimed at improving patient outcomes.

Tethis S.p.A. is an Italian company based in Milan that specializes in the development, manufacturing, and sale of in vitro diagnostic devices, particularly for fluorescent in situ hybridization (FISH) assays. Founded in 2004, Tethis operates within the bio- and nanotechnology sectors, offering a range of products, including a proprietary coated slide with microfluidic compartments, an automated slide staining system, and an instrument that facilitates key steps in the FISH protocol. The company's innovative diagnostic device enables the detection of circulating tumor cells through liquid biopsy, supporting early cancer diagnosis and personalized medicine. Tethis S.p.A. aims to improve clinical outcomes by providing tools for targeted therapy and monitoring minimal residual disease, thereby contributing to the advancement of healthcare solutions.

Gradientech AB is a biotech company based in Uppsala, Sweden, specializing in the development and supply of microfluidic products for analyzing cell migration and behavior in response to signaling gradients. The company offers a range of CellDirector products designed for research applications, including the CellDirector Opal and CellDirector Ruby, which facilitate studies on endothelial cell migration, angiogenesis, and tumor cell behavior. Additionally, Gradientech provides complementary tools such as Gradient Marker solutions for visualizing gradient formation, a syringe pump for precise fluid delivery, and a vacuum pump for conducting experiments at elevated temperatures. The company also features the QuickMIC® system for ultra-rapid antibiotic susceptibility testing, which enhances the capabilities of microbiology labs by delivering reliable minimum inhibitory concentration results swiftly. Gradientech serves scientists across academic, pharmaceutical, and diagnostic markets globally, and its products are available for purchase online. The company was incorporated in 2009.

Lyme Diagnostics offers reliable, standard diagnostic system for diagnosing Lyme borreliosis. Lyme diagnostics is primarily focused on the more exact, routine diagnostics of Lyme disease, building on the innovative technologies developed by the diagnostic & therapeutic workgroup of the Lyme Borreliosis Foundation. We offer the results of 30 years of work by 8 medical professionals. Currently, our novel diagnostic methods are supplemented with laboratory-standard, widely-accepted diagnostic procedures, and carefully confirmed by clinical diagnosis. The company's objective is that - after clinical testing - we will be able to offer one single screening method across Europe, and in North America.

PharmaBiome AG is a biotechnology company based in Zurich, Switzerland, focused on developing innovative treatments for gastrointestinal diseases. Founded in 2015, the company specializes in the isolation and characterization of novel intestinal microbes to create microbiome therapies aimed at conditions such as Clostridium difficile infections, cancer, and ulcerative colitis. PharmaBiome's technology platform enables efficient development and production of defined, function-based therapies, facilitating a swift transition from identifying therapeutic mechanisms to clinical-ready products. The company aims to establish microbiota therapy as the new standard for treating intestinal diseases, providing alternatives to traditional fecal transplants for patients suffering from intestinal infections.

Beactica Therapeutics, established in 2006 and headquartered in Uppsala, Sweden, specializes in precision oncology, focusing on the discovery and development of novel small molecule therapeutics for genetically defined cancers with significant unmet clinical need. The company's core expertise lies in SPR biosensor-based small molecule drug discovery, leveraging molecular interaction analysis and structural information to advance drug leads. Beactica's pipeline comprises novel small molecule inhibitors and targeted protein degraders (PROTACs), with a strategic partnership with Dong-A ST Co., Ltd. The company aims to deliver value to patients and shareholders by progressing its programs into early clinical trials, ultimately improving cancer treatment efficiency and reducing risks.

Lisapharma S.p.A., founded in 1925 and based in Erba, Italy, specializes in the manufacture of sterile injectable drugs, non-sterile liquids, semisolids, medical devices, and veterinary products. Operating in over 40 countries, the company plays a significant role in the global pharmaceutical market. Lisapharma's manufacturing facility adheres to Good Manufacturing Practice (GMP) standards, ensuring compliance in both domestic and international markets. The company holds various Marketing Authorizations for its internally produced products and also serves as a contract manufacturer for both Italian and multinational clients. In 2019, Lisapharma became a subsidiary of Shandong Sito Bio-technology Co., Ltd., following its acquisition by Italian private equity funds in 2015.

Braingineering Technologies is an innovative biotech company that provides pharmaceutical companies with drug screening services in drug discovery and pre-clinical testing for Parkinson’s disease. Braingineering Technologies offers a new high-tech in vitro Brain-on-a-Chip technology and brain organoid technology that increases efficiency and relevance in the drug development process. Both technologies are based on the utilization of disease specific human induced pluripotent stem cells.

HAWK Biosystems specializes in cancer diagnostics through a companion diagnostics platform that identifies post-translational modifications and protein-protein interactions in pathology samples. The platform quantifies these interactions in single-cell and fixed tissue samples, maintaining the integrity and heterogeneity of the tissue. This technology offers medical practitioners and pharmaceutical companies a novel approach to treatment decisions, particularly in cancer, inflammation, and immune disorders. HAWK Biosystems aims to enhance precision medicine by enabling targeted therapies that match patients with the treatments most likely to be effective, thereby improving patient outcomes, quality of life, and reducing overall drug costs. The company seeks to establish collaborative opportunities within the European health system to further its impact in the field.

ISS BioSense operates in the field of biotechnology as applied to biosensors. ISS BioSense is a new high-tech SME located in Naples, Italy. The company was born on the initiative of a group of young scientists that decided to apply the expertise acquired in research institutions to biosensors design and development. For the advancement of its projects, ISS BioSense operates in synergy with national and international Research Institutions as well as with private enterprises. The main cultural and technological assets of ISS BioSense are its knowledge and expertise about the use and the manipulation of molecules of biological origin to develop highly specific and sensitive sensors.

InfiCure Bio is a life science company based in Umeå, Sweden, specializing in the preclinical development and validation of drugs aimed at chronic inflammatory and fibrotic conditions. Founded in 2015, it evolved from a project initiated at the Umeå Biotech Incubator by Prof. Dan Holmberg and Dr. Sofia Mayans, leveraging research from their academic work. The company provides a unique preclinical model that simulates the development of fibrosis in various organs, such as the liver and kidneys, which is often preceded by chronic inflammation. This model allows pharmaceutical companies to test their anti-inflammatory and anti-fibrotic drugs comprehensively. InfiCure Bio's services include the setup, execution, analysis, and reporting of results from these effect tests, thereby supporting the development of therapies for significant medical conditions like chronic liver and kidney diseases.

Genomic Expression Inc., established in 2009 and headquartered in Beverly, Massachusetts, specializes in developing cancer diagnostics. The company's core technology, OneRNA, employs RNA sequencing to help healthcare professionals select the most effective drug treatments for their patients. By analyzing RNA, Genomic Expression aims to detect diseases, monitor health, and design next-generation cures, offering a paradigm shift in personalized medicine.

SDS Optic, based in Lublin, is an innovative biotech company that develops advanced diagnostic solutions aimed at improving cancer detection and treatment. The company operates at the intersection of biochemistry, engineering, and fiber optic technologies, creating methodologies for in-vivo cancer diagnosis with single-cell resolution. SDS Optic specializes in the pre-assembly of both hermetic and standard photoelectronics components, contributing to the efficiency and effectiveness of its diagnostic tools. By focusing on novel approaches in oncology, the company addresses the pressing needs of patients and healthcare providers, striving for quicker and less painful diagnostic processes.

Ilya Pharma AB, established in 2016 and headquartered in Uppsala, Sweden, specializes in the development of biological drugs for treating skin and mucosal wounds. The company's innovative approach involves genetically modifying lactic acid bacteria, commonly found in yogurt, to produce substances that accelerate wound healing. Ilya Pharma focuses on both acute and chronic wounds, with a particular emphasis on addressing the unique challenges faced by diabetic patients. The company's work is grounded in extensive scientific research conducted at Uppsala University and the Swedish University of Agriculture.

SymCel is a manufacturer of scientific instruments that specializes in providing innovative tools for real-time cellular bioenergetic measurements. The company develops and markets a label-free assay technology that enables continuous monitoring of cell metabolism and biological activity, including the heat produced by living cells. This technology addresses a critical gap in the field of cell biological research and development, catering to both R&D departments in the life sciences industry and academic research laboratories. By offering a fast and accurate method for data collection, SymCel’s instruments empower researchers and clinicians to uncover new insights into cellular processes, enhancing the understanding of metabolism and its implications in various biological contexts.

Protobios is an Estonian biotechnology company that develops technologies in the field of cell biology and immunology.

Gnubiotics Sciences SA specializes in developing microbiome-modulating products aimed at nurturing, maintaining, and restoring microbiome diversity in humans and animals. Founded in 2016 and based in Epalinges, Switzerland, the company produces glycans and functional mimics of Human Milk Oligosaccharides (HMOs) for the consumer health market. Their flagship product, AMObiomeTM, is designed to enhance microbiome diversity and promote lifelong gut health. By replicating the natural structures found in breast milk, Gnubiotics aims to prevent infections and combat diet-induced obesity, while also addressing the growing demand for healthier food options. The company's innovative approach focuses on supporting immune systems and overall well-being through natural microbiome modulation.

GeneFirst is a molecular diagnostics company specializing in infectious disease, cancer diagnostics, and personalized medicine. The company develops sensitive and affordable diagnostic technologies and products aimed at researchers, clinicians, and pharmaceutical companies. GeneFirst's innovative platform allows for the simultaneous detection of multiple targets in a single reaction, enhancing the accuracy of diagnoses and facilitating the delivery of safe and effective treatments. By providing easy-to-use diagnostic solutions, GeneFirst aims to improve patient outcomes and support advancements in medical science.